{"filing":{"accession_number":"0001193125-26-336767","cik":"0001835597","ticker":"PEPG","company_name":"PepGen Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"pepg-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1835597/000119312526336767/pepg-20260806.htm"},"events":[{"id":25552,"run_id":23194,"accession_number":"0001193125-26-336767","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.94,"summary":"PepGen disclosed Q2 2026 financial results via press release, reporting a net loss of $17.8 million (improved from $23.1 million in Q2 2025), R\u0026D expenses of $12.5 million, and a cash position of $117.2 million, along with condensed consolidated financial statements and per-share metrics.","company_name":"PepGen Inc.","ticker":"PEPG","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26419,"accession_number":"0001193125-26-336767","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"PepGen disclosed its Q2 2026 financial results via a press release titled \"PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights,\" including condensed consolidated statements of operations and balance sheets showing net loss of $17.8 million (vs. $23.1 million in Q2 2025), R\u0026D expenses of $12.5 million, and cash position of $117.2 million. This is a standard quarterly earnings release under Item 2.02, material to investors assessing the company's financial condition and runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:54:32.075093+00:00","company_name":"","ticker":null,"filing_date":""},{"id":26420,"accession_number":"0001193125-26-336767","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"PepGen disclosed Q2 2026 financial results (net loss of $17.8M, cash position of $117.2M, operating expenses) and recent corporate highlights including clinical trial progress for PGN-EDODM1. The filing includes a full earnings press release (EX-99.1) with condensed consolidated financial statements and per-share metrics, which is the hallmark of an earnings_release disclosure under Item 7.01 (Regulation FD Disclosure).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:54:32.075093+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":25553,"run_id":23194,"accession_number":"0001193125-26-336767","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"PepGen announced that an independent Data and Safety Monitoring Board recommended advancing its Phase 2 FREEDOM2-DM1 study into the highest dose cohort (12.5 mg/kg) and dose escalation in the open-label extension study from 5 mg/kg to 10 mg/kg, representing a material clinical development milestone for the lead candidate PGN-EDODM1.","company_name":"PepGen Inc.","ticker":"PEPG","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26421,"accession_number":"0001193125-26-336767","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"PepGen announced that an independent Data and Safety Monitoring Board recommended advancing its Phase 2 FREEDOM2-DM1 study into the highest dose cohort (12.5 mg/kg) and dose escalation in the open-label extension study from 5 mg/kg to 10 mg/kg. This represents a material clinical development milestone for the company's lead candidate PGN-EDODM1, reflecting positive safety data and regulatory progress that would affect a reasonable investor's assessment of the program's advancement and commercial potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:54:32.075093+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26419,"accession_number":"0001193125-26-336767","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"PepGen disclosed its Q2 2026 financial results via a press release titled \"PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights,\" including condensed consolidated statements of operations and balance sheets showing net loss of $17.8 million (vs. $23.1 million in Q2 2025), R\u0026D expenses of $12.5 million, and cash position of $117.2 million. This is a standard quarterly earnings release under Item 2.02, material to investors assessing the company's financial condition and runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:54:32.075093+00:00","company_name":"PepGen Inc.","ticker":"PEPG","filing_date":"2026-08-06"},{"id":26420,"accession_number":"0001193125-26-336767","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"PepGen disclosed Q2 2026 financial results (net loss of $17.8M, cash position of $117.2M, operating expenses) and recent corporate highlights including clinical trial progress for PGN-EDODM1. The filing includes a full earnings press release (EX-99.1) with condensed consolidated financial statements and per-share metrics, which is the hallmark of an earnings_release disclosure under Item 7.01 (Regulation FD Disclosure).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:54:32.075093+00:00","company_name":"PepGen Inc.","ticker":"PEPG","filing_date":"2026-08-06"},{"id":26421,"accession_number":"0001193125-26-336767","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"PepGen announced that an independent Data and Safety Monitoring Board recommended advancing its Phase 2 FREEDOM2-DM1 study into the highest dose cohort (12.5 mg/kg) and dose escalation in the open-label extension study from 5 mg/kg to 10 mg/kg. This represents a material clinical development milestone for the company's lead candidate PGN-EDODM1, reflecting positive safety data and regulatory progress that would affect a reasonable investor's assessment of the program's advancement and commercial potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:54:32.075093+00:00","company_name":"PepGen Inc.","ticker":"PEPG","filing_date":"2026-08-06"}]}